In contrast to antibodies targeting amyloid-β (54, 55) or tau (56) for the treatment of Alzheimer disease (57) or α-synuclein for the treatment of Parkinson's disease (58, 59), targeting a specific misfolded myocilin species may not be required to promote mutant myocilin degradation. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.